Matching articles for "Ortikos"

In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
An oral extended-release formulation of the corticosteroid budesonide (Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending...
An oral extended-release formulation of the corticosteroid budesonide (Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon in patients ≥8 years old and for maintenance of remission for up to 3 months in adults. Ortikos is the second oral formulation of budesonide to be approved for this indication; Entocort EC, an ileal-release formulation, was the first. A third oral formulation of budesonide (Uceris) is approved for induction of remission in patients with mild to moderate active ulcerative colitis.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):176 | Show Full IntroductionHide Full Introduction